OmniaBio Inc. announced the opening of a new North American cell and gene therapy manufacturing and artificial intelligence center of excellence, which is now Canada’s largest contract development and manufacturing organization facility dedicated to CGT.Â
Together for Supportive Cancer Care, a national coalition that will work to expand early, equitable access to whole-person, supportive care for all people with cancer, regardless of where they receive care, has launched.
FDA in collaboration with U.S. Customs and Border Protection, announced the administrative seizure of approximately three million units of unauthorized e-cigarette products, with an estimated retail value of $76 million.Â
New research published in the Journal of the National Comprehensive Cancer Network found that people with newly-diagnosed hormone receptor-negative, human epidermal growth factor receptor 2-positive breast cancer were more likely to receive timely, guideline-concordant treatment, and have longer survival in states that participate in Medicaid expansion under the Affordable Care Act.
Cutting off cancer cells’ access to fat may help a specific type of cancer treatment work more effectively, reports a study by Van Andel Institute scientists. Â
Molecular markers in blood at birth are linked to later development of acute lymphoblastic leukemia, the most common cancer type that affects children, according to a study published in Molecular Cancer.Â
Preclinical data on a development candidate, NTX-452, a novel Werner syndrome helicase inhibitor, was presented at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, by Nimbus Therapeutics.Â
Inflo Health, a leader in AI-driven radiology follow-up care orchestration, announced that it has qualified for the American College of Radiology’s Learning Network Vendor Partner designation on the heels of a successful collaboration that saw East Alabama Medical Center significantly improve recommendations follow-up rates.Â
FDA has approved Vyloy (zolbetuximab-clzb), a claudin 18.2-directed cytolytic antibody, with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2-negative gastric or gastroesophageal junction adenocarcinoma whose tumors are CLDN18.2 positive, as determined by an FDA-approved test.
FDA has accepted the New Drug Application for TLX101-CDx (Pixclara), an agent for the imaging of glioma.Â
